Laurie Bibens

Mrs. Laurie Bibens

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 March 2023 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
LBLaurie Bibens
Laurie Bibens
JBJean-Paul Becker
Jean-Paul Becker
Alexandra Dassonville-KlimptAlexandra Dassonville-Klimpt
Alexandra Dassonville-Klimpt
Pascal SonnetPascal Sonnet
Pascal Sonnet
Resistance to antimicrobial drugs is currently a serious threat to human health. Consequently, we are facing an urgent need for new antimicrobial drugs acting with original modes of action. The ubiquitous and widely conserved microbial fatty acid biosynthesis pathway, called FAS-II system, represents a potential target to tackle antimicrobial resistance. This pathway has been extensively studied, and eleven proteins have been described. FabI (or InhA, its homologue in mycobacteria) was considered as a prime target by many teams and is currently the only enzyme with commercial inhibitor drugs: triclosan and isoniazid. Furthermore, afabicin and CG400549, two promising compounds which also target FabI, are in clinical assays to treat Staphylococcus aureus. However, most of the other enzymes are still underexploited targets. This review, after presenting the FAS-II system and its enzymes in Escherichia coli, highlights the reported inhibitors of the system. Their biological activities, main interactions formed with their targets and structure–activity relationships are presented as far as possible.

1 November 2022 in Medical Sciences Forum
Verified
Conference Paper
Open access
PDF file
LBLaurie Bibens
Laurie Bibens
JBJean-Paul Becker
Jean-Paul Becker
NLNadine Lemaître
Nadine Lemaître
FPFrançois Peltier
François Peltier
VMVirginie Morel
Virginie Morel
Pascal SonnetPascal Sonnet
Pascal Sonnet
At present, antimicrobial resistance is one of the most significant public health challenges